Capricor Therapeutics (CAPR) Non Operating Income (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Non Operating Income of $2.8 million for Q1 2026, up 378.82% year-over-year from $591354.0 in Q1 2025, and up 379.43% quarter-over-quarter from -$1.0 million in Q4 2025.
Capricor Therapeutics (CAPR) Non Operating Income (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Non Operating Income history runs 17 years deep, the most recent figure standing at $2.8 million for Q1 2026.
- In Q1 2026, Non Operating Income rose 378.82% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $5.3 million (up 140.84% YoY), while the FY2025 annual figure was $3.1 million, up 47.77% from the prior year.
- Non Operating Income for Q1 2026 stood at $2.8 million, up from -$1.0 million in the prior quarter.
- The five-year high for Non Operating Income was $2.8 million in Q1 2026, with the low at -$1.0 million in Q4 2025.
- The 5-year median for Non Operating Income is $471829.0 (2024), against an average of $617477.4.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income jumped 2998.53% in 2023, then sank 274.34% in 2025.
- Capricor Therapeutics' Non Operating Income stood at $345433.0 in 2022, then soared by 50.3% to $519203.0 in 2023, then advanced by 11.95% to $581238.0 in 2024, then tumbled by 274.34% to -$1.0 million in 2025, then surged by 379.43% to $2.8 million in 2026.
- Business Quant data shows CAPR's Non Operating Income at $2.8 million in Q1 2026, -$1.0 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | 2.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.83 Mn |
| Dec 31, 2025 | -1.01 Mn |
| Sep 30, 2025 | 1.71 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | 591,354.00 |
| Dec 31, 2024 | 581,238.00 |
| Sep 30, 2024 | 453,152.00 |
| Jun 30, 2024 | 591,437.00 |
| Mar 31, 2024 | 471,829.00 |
| Dec 31, 2023 | 519,203.00 |
| Sep 30, 2023 | 473,992.00 |
| Jun 30, 2023 | 380,680.00 |
| Mar 31, 2023 | 416,442.00 |
| Dec 31, 2022 | 345,433.00 |
| Sep 30, 2022 | 106,635.00 |
| Jun 30, 2022 | 212,343.00 |
| Mar 31, 2022 | 13,440.00 |
| Dec 31, 2021 | 189,118.00 |
| Sep 30, 2021 | 382,738.00 |
| Jun 30, 2021 | 334,901.00 |